ZA201401159B - Peg-interferon lambda 1 conjugates - Google Patents

Peg-interferon lambda 1 conjugates

Info

Publication number
ZA201401159B
ZA201401159B ZA2014/01159A ZA201401159A ZA201401159B ZA 201401159 B ZA201401159 B ZA 201401159B ZA 2014/01159 A ZA2014/01159 A ZA 2014/01159A ZA 201401159 A ZA201401159 A ZA 201401159A ZA 201401159 B ZA201401159 B ZA 201401159B
Authority
ZA
South Africa
Prior art keywords
conjugates
peg
interferon lambda
interferon
lambda
Prior art date
Application number
ZA2014/01159A
Other languages
English (en)
Inventor
Nhan Ho
Original Assignee
Nanogen Pharmaceutical Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanogen Pharmaceutical Biotechnology filed Critical Nanogen Pharmaceutical Biotechnology
Publication of ZA201401159B publication Critical patent/ZA201401159B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/555Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ZA2014/01159A 2011-08-25 2014-02-14 Peg-interferon lambda 1 conjugates ZA201401159B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
VN201102222 2011-08-25
PCT/US2012/027317 WO2013028233A1 (en) 2011-08-25 2012-03-01 Peg-interferon lambda 1 conjugates

Publications (1)

Publication Number Publication Date
ZA201401159B true ZA201401159B (en) 2015-04-29

Family

ID=47746747

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2014/01159A ZA201401159B (en) 2011-08-25 2014-02-14 Peg-interferon lambda 1 conjugates

Country Status (9)

Country Link
EP (1) EP2748328A4 (cg-RX-API-DMAC7.html)
JP (1) JP2014525939A (cg-RX-API-DMAC7.html)
CN (1) CN103228792A (cg-RX-API-DMAC7.html)
AU (1) AU2012299423A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014004302A2 (cg-RX-API-DMAC7.html)
CA (1) CA2846092A1 (cg-RX-API-DMAC7.html)
RU (1) RU2014111179A (cg-RX-API-DMAC7.html)
WO (1) WO2013028233A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201401159B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10953072B2 (en) 2016-02-19 2021-03-23 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection with interferon lambda
EP3375452B1 (en) 2017-03-16 2025-01-08 Evangelos Andreakos Use of lambda interferons in the treatment of an obesity-related disorder, atherosclerosis or a coagulation disorder
RU2678332C1 (ru) * 2017-09-08 2019-01-28 Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "СФМ") Пегилированный интерферон лямбда, обладающий высокой биодоступностью при пероральном применении, и способ его получения
CN112245570A (zh) 2019-07-22 2021-01-22 厦门特宝生物工程股份有限公司 一种基于干扰素的疾病治疗方法
KR20230157313A (ko) 2021-01-21 2023-11-16 샤먼 아모이탑 바이오테크 컴퍼니 리미티드 인터페론-기반 암 치료 방법 및 약제학적 조합
CA3206005A1 (en) 2021-01-21 2022-07-28 Xiaojin Liao Method and pharmaceutical combination for preventing cancer recurrence
EP4630027A1 (en) 2022-12-09 2025-10-15 DYS-Immune Therapeutics Composite aids vaccine generating anti-hiv specific neutralizing antibodies and/or anti-hiv cytotoxic t cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
CN1176137C (zh) * 2002-01-15 2004-11-17 泛亚生物技术有限公司 多臂树杈型功能化聚乙二醇制备方法及它在药物中的应用
CN1927388B (zh) * 2004-09-10 2011-02-02 北京金迪克生物技术研究所 含有人干扰素的药物组合物
MX2007015058A (es) * 2005-06-03 2008-01-28 Ambrx Inc Moleculas de interferon humano mejoradas y sus usos.
WO2007041713A1 (en) * 2005-10-04 2007-04-12 Zymogenetics, Inc. Production and purification of il-29
CN101002942B (zh) * 2007-01-08 2010-07-21 湖南大学 一种peg化脂质体纳米颗粒
EP2296691A1 (en) * 2008-06-05 2011-03-23 ZymoGenetics, L.L.C. Use of pegylated type iii interferons for the treatment of hepatitis c

Also Published As

Publication number Publication date
RU2014111179A (ru) 2015-09-27
EP2748328A1 (en) 2014-07-02
EP2748328A4 (en) 2015-03-04
CN103228792A (zh) 2013-07-31
BR112014004302A2 (pt) 2017-06-20
JP2014525939A (ja) 2014-10-02
WO2013028233A1 (en) 2013-02-28
AU2012299423A1 (en) 2014-03-06
CA2846092A1 (en) 2013-02-28

Similar Documents

Publication Publication Date Title
ZA201401159B (en) Peg-interferon lambda 1 conjugates
FR2971446B3 (fr) Coiff'rasoir
GB201114544D0 (en) Concept 25
GB201114558D0 (en) Concept 43
GB201114522D0 (en) Concept 32
GB201114519D0 (en) Concept 31
GB201114517D0 (en) Concept 15
GB201114511D0 (en) Concept 7
GB201114503D0 (en) Concept 54
GB201114502D0 (en) Concept 53
GB201114489D0 (en) Concept 12 12
GB201114487D0 (en) Concept 16
GB201114486D0 (en) Concept 6
GB201114480D0 (en) Concept 9
GB201114478D0 (en) Concept 11
GB201114472D0 (en) Concept 14
GB201104317D0 (en) Concept 61
GB201104316D0 (en) Concept 60
GB201103885D0 (en) Concept 58
GB201103884D0 (en) Concept 59
GB201101156D0 (en) Concept 57
GB201100371D0 (en) Concept 15
GB201100366D0 (en) Concept 12 12
GB201114529D0 (en) Concept 34
GB201114530D0 (en) Concept 35